Viking Therapeutics - Press Releases
WEBJul 24, 2024 · Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
News & Events - Viking Therapeutics InvestorRoom
WEBFeb 27, 2024 · Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity. Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo.
Why Viking Therapeutics Stock Was So Healthy on Wednesday
WEB1 day ago · Viking Therapeutics (VKTX 1.94%), a biotech stock that has rocketed to prominence thanks to one of its investigational drugs, gave investors more reason to like it on Wednesday.
Why Viking Therapeutics Stock Was So Healthy on Wednesday
WEB1 day ago · Viking Therapeutics (NASDAQ: VKTX), a biotech stock that has rocketed to prominence thanks to one of its investigational drugs, gave investors more reason to like it on Wednesday.
Viking Therapeutics, Inc. (VKTX) Latest Stock News & Headlines
WEBGet the latest Viking Therapeutics, Inc. (VKTX) stock news and headlines to help you in your trading and investing decisions.
Viking Therapeutics Is A Buy For Some Investors, But Beware The ...
WEB1 day ago · Viking Therapeutics' weight-loss drug VK2735 shows strong efficacy, likely leading to an acquisition by a large pharmaceutical firm, in my opinion.
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some …
WEB1 day ago · In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $63.13, with a +1.94% movement compared to the previous day. The stock's performance was ahead of the S&P 500's daily loss...
Viking Therapeutics: Market Excited By GLP-1 Promise - Seeking …
WEB2 days ago · Viking Therapeutics, Inc. stock has surged nearly 1,500% since 2023, driven by the promising GLP-1/GIP receptor agonist VK-2735 for obesity. VK-2735's Phase 2 data showed weight loss comparable...
Viking Therapeutics Reports First Quarter 2024 Financial Results …
WEBSAN DIEGO, April 24, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
News & Events - Viking Therapeutics InvestorRoom
WEBMar 28, 2023 · Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735. Up to 6.0% Placebo-Adjusted Mean Weight Loss (7.8% From Baseline) Observed After 28 Days. VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study. Phase 2 Trial in Obesity Planned for Mid-2023.
Skip to content